NewcelX Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 1.2
- Dividend yield
- –
About NewcelX
Pharmaceutical Preparations, SIC 2834
NewcelX Ltd. is a clinical-stage biopharmaceutical enterprise specializing in the development and manufacture of proprietary, allogeneic, off-the-shelf cell therapy products. Utilizing a proprietary technology platform designed for expanding and differentiating human embryonic stem cells (hESCs) into functional cells, the firm advances regenerative medicine candidates. Its clinical-stage pipeline features therapeutic programs such as NCEL-101 and AstroRx. Because its candidates remain in the clinical development and evaluation phases, the company does not yet market commercial products or generate commercial revenue, aiming ultimately to serve patients and healthcare providers through clinical collaborations and specialized medical partnerships.
The company operates corporate offices in Switzerland along with a wholly owned subsidiary in Delaware and research and development facilities in Israel. Formerly known as NLS Pharmaceutics Ltd., the organization adopted its current name following a merger with Israeli biotechnology firm Kadimastem Ltd. Corporate executive offices and management are based in Kloten, Switzerland.
Summary of the business section of NewcelX's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NewcelX Ltd.
- Founded
- 2008
- Headquarters
- Zurich, Switzerland
- Address
- The Circle 6, 8058
- Phone
- 41-41-618-80-00
- Website
- newcelx.com
- Employees
- 12, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- V8
- Fiscal year ends
- December 31
- Auditor
- Kost Forer Gabbay & Kasierer, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- NCEL
- Exchange
- Nasdaq
- IPO date
- Feb 1, 2021
- Shares outstanding
- 5M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Oct 31, 2025; 1-for-40 reverse, Oct 18, 2024; 1-for-40 reverse, Sep 27, 2024
- SEC CIK
- 1783036
- CUSIP
- H57830103
- ISIN
- USH578301030
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michel Revel | CSO and Director | 957,530 |
| Ronen Twito | Chairman and CEO, Director | 272,399 |
| Kfir Molakandov | VP of R&D | – |
| Omri Hagai | Chief Financial Officer | – |
| Olivier Samuel | Director | 81,818 |
| Tamar Galili | Director | – |
| Alexander Zwyer | Director | – |
| Eran Israel Iohan | Director | – |
| Liora Oren | Director | – |
Employees
Headcount reported in annual reports
“NewcelX and its subsidiaries had 12 employees, nine of whom are employed on a full-time basis and three employed on a part-time basis.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 30, 2025 | Name change | Name changed from NLS Pharmaceutics Ltd. to NewcelX Ltd. |
| May 1, 2025 | Late filing | Notification of late filing |
| Dec 30, 2024 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Apr 30, 2024 | Late filing | Notification of late filing |
| May 1, 2023 | Late filing | Notification of late filing |
| Apr 30, 2021 | Late filing | Notification of late filing |
| Feb 1, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 28, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |